Q4 sales strongly rose +16% to €3,464m, but gross profit margin slightly weakened from 67.0% to 66.8%. EBITDA stood unchanged at €803m, but net profit attributable to shareholders more than halved (-55% to €126m). Operating CF clearly dropped by 37% to €718m, seeing much lower NWC inflow (€71m after €465m). Reflecting the payment for Sigma-Aldrich, investing CF ended up at €-14,605m (€-1,144m) and financing CF rose from €1,519m to €2,833m. Man
08 Mar 2016
Healthcare remains weak, Life Science becomes the new shining star
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthcare remains weak, Life Science becomes the new shining star
Merck KGaA (MRCK:WBO) | 0 0 1.2% | Mkt Cap: 10,792m
- Published:
08 Mar 2016 -
Author:
Martin Schnee -
Pages:
3
Q4 sales strongly rose +16% to €3,464m, but gross profit margin slightly weakened from 67.0% to 66.8%. EBITDA stood unchanged at €803m, but net profit attributable to shareholders more than halved (-55% to €126m). Operating CF clearly dropped by 37% to €718m, seeing much lower NWC inflow (€71m after €465m). Reflecting the payment for Sigma-Aldrich, investing CF ended up at €-14,605m (€-1,144m) and financing CF rose from €1,519m to €2,833m. Man